TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
SANTA MONICA, Calif., Jan. 06, 2016 (GLOBE NEWSWIRE) -- Kite Pharma, Inc. (NASDAQ:KITE) today announced that Arie Belldegrun, M.D., FACS, Chairman, President and Chief Executive Officer, will present at the 34th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2016 at 8:30 AM Pacific Time. The event will be held in San Francisco at the Westin St. Francis Hotel.
The presentation will be webcasted and will be available through the Calendar of Events section of Kite's website at ir.kitepharma.com.
About Kite Pharma, Inc.
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Kite Pharma, Inc. Cynthia M. Butitta Chief Financial Officer and Chief Operating Officer 310-824-9999 For Media: Justin Jackson For Investor Inquiries: Lisa Burns Burns McClellan (212) 213-0006 [email protected] [email protected]
